Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GLG1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GLG1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GLG1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GLG1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GLG1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GLG1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GLG1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GLG1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GLG1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GLG1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
GO:00516048 | Cervix | CC | protein maturation | 56/2311 | 294/18723 | 5.90e-04 | 5.59e-03 | 56 |
GO:00715595 | Cervix | CC | response to transforming growth factor beta | 50/2311 | 256/18723 | 6.31e-04 | 5.91e-03 | 50 |
GO:00715605 | Cervix | CC | cellular response to transforming growth factor beta stimulus | 49/2311 | 250/18723 | 6.55e-04 | 6.05e-03 | 49 |
GO:00071795 | Cervix | CC | transforming growth factor beta receptor signaling pathway | 38/2311 | 198/18723 | 3.62e-03 | 2.31e-02 | 38 |
GO:004586124 | Cervix | N_HPV | negative regulation of proteolysis | 27/534 | 351/18723 | 3.27e-06 | 1.36e-04 | 27 |
GO:007156023 | Cervix | N_HPV | cellular response to transforming growth factor beta stimulus | 18/534 | 250/18723 | 3.16e-04 | 4.75e-03 | 18 |
GO:005160414 | Cervix | N_HPV | protein maturation | 20/534 | 294/18723 | 3.17e-04 | 4.75e-03 | 20 |
GO:007155923 | Cervix | N_HPV | response to transforming growth factor beta | 18/534 | 256/18723 | 4.21e-04 | 5.88e-03 | 18 |
GO:000717821 | Cervix | N_HPV | transmembrane receptor protein serine/threonine kinase signaling pathway | 22/534 | 355/18723 | 5.85e-04 | 7.73e-03 | 22 |
GO:00603482 | Cervix | N_HPV | bone development | 15/534 | 205/18723 | 8.27e-04 | 1.02e-02 | 15 |
GO:000717922 | Cervix | N_HPV | transforming growth factor beta receptor signaling pathway | 14/534 | 198/18723 | 1.69e-03 | 1.72e-02 | 14 |
GO:00164854 | Cervix | N_HPV | protein processing | 15/534 | 225/18723 | 2.09e-03 | 2.00e-02 | 15 |
GO:0045861 | Colorectum | AD | negative regulation of proteolysis | 106/3918 | 351/18723 | 2.33e-05 | 4.57e-04 | 106 |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:0007178 | Colorectum | AD | transmembrane receptor protein serine/threonine kinase signaling pathway | 99/3918 | 355/18723 | 9.92e-04 | 9.28e-03 | 99 |
GO:0071559 | Colorectum | AD | response to transforming growth factor beta | 74/3918 | 256/18723 | 1.45e-03 | 1.23e-02 | 74 |
GO:0071560 | Colorectum | AD | cellular response to transforming growth factor beta stimulus | 72/3918 | 250/18723 | 1.85e-03 | 1.52e-02 | 72 |
GO:0007179 | Colorectum | AD | transforming growth factor beta receptor signaling pathway | 59/3918 | 198/18723 | 1.94e-03 | 1.58e-02 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLG1 | SNV | Missense_Mutation | novel | c.1317N>T | p.Glu439Asp | p.E439D | Q92896 | protein_coding | tolerated(0.16) | probably_damaging(0.982) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
GLG1 | SNV | Missense_Mutation | novel | c.3058N>C | p.Glu1020Gln | p.E1020Q | Q92896 | protein_coding | tolerated(0.09) | probably_damaging(0.986) | TCGA-63-A5MT-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
GLG1 | SNV | Missense_Mutation | | c.2711N>G | p.Leu904Trp | p.L904W | Q92896 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-66-2771-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR |
GLG1 | SNV | Missense_Mutation | novel | c.468T>G | p.Asn156Lys | p.N156K | Q92896 | protein_coding | tolerated(0.11) | benign(0.365) | TCGA-85-A510-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GLG1 | SNV | Missense_Mutation | novel | c.1802N>T | p.Tyr601Phe | p.Y601F | Q92896 | protein_coding | tolerated(0.06) | benign(0.318) | TCGA-90-7767-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GLG1 | SNV | Missense_Mutation | novel | c.3190N>C | p.Asp1064His | p.D1064H | Q92896 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-NC-A5HD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GLG1 | insertion | Frame_Shift_Ins | novel | c.568_569insAT | p.Cys190TyrfsTer35 | p.C190Yfs*35 | Q92896 | protein_coding | | | TCGA-55-8299-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
GLG1 | SNV | Missense_Mutation | novel | c.1640N>C | p.Leu547Ser | p.L547S | Q92896 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GLG1 | SNV | Missense_Mutation | novel | c.3500N>T | p.Arg1167Leu | p.R1167L | Q92896 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CN-6010-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
GLG1 | SNV | Missense_Mutation | | c.1448N>A | p.Ala483Glu | p.A483E | Q92896 | protein_coding | tolerated(0.2) | probably_damaging(0.994) | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |